NCT04685070 2024-08-14Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung CancerShanghai Pulmonary Hospital, Shanghai, ChinaPhase 2 Active not recruiting56 enrolled